42 results on '"Devenport, Jenny"'
Search Results
2. Do you want to stay single? Considerations on single arm trials in drug development and the post-regulatory space
3. Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis
4. Leading beyond regulatory approval: Opportunities for statisticians to optimize evidence generation and impact clinical practice.
5. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
6. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis
7. Additional file 2 of Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis
8. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
9. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls
10. Analysis of construction worker injuries that do not result in lost time
11. Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab
12. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
13. Effects of Dose Escalation of Tocilizumab in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: Sub-Analysis of a 24-Week Study in a United States Population.: 1323
14. Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population.: 1300
15. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis
16. Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’
17. A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens
18. Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy
19. The Effects of Splinting on Outcomes for Epicondylitis
20. Appendix -Supplemental material for Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design
21. OP0086 IMPACT OF GLUCOCORTICOID TAPERING ON MARKERS OF BONE METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB: EXPLORATORY ANALYIS FROM A RANDOMIZED CONTROLLED TRIAL
22. AB0277 EFFECT OF DISEASE DURATION AND OTHER PATIENT BASELINE CHARACTERISTICS ON OUTCOMES IN TOCILIZUMAB-TREATED RHEUMATOID ARTHRITIS PATIENTS: A POOLED ANALYSIS
23. AB0234 AN INTEGRATED PROTEOMICS AND ANTIBODY ANALYSIS OF THE U-ACT-EARLY TRIAL TO IDENTIFY MARKERS OF TREATMENT RESPONSE AND DISEASE PROGRESSION IN EARLY RHEUMATOID ARTHRITIS
24. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice
25. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
26. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.
27. Case Reports1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility
28. Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design
29. Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)
30. Correction of: Exploring Concordance of Patient-Reported Information on PatientsLikeMe and Medical Claims Data at the Patient Level
31. Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
32. Exploring Concordance of Patient-Reported Information on PatientsLikeMe and Medical Claims Data at the Patient Level
33. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
34. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis
35. The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
36. Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment
37. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study
38. Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'.
39. Poster 20
40. Poster 20: The Association of Preservative Uptake Profiles With Corneal Staining in Various Lens/Solution Combinations
41. Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space.
42. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.